We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Fast, Accurate Test Aids in Detection of Lynch Syndrome

By LabMedica International staff writers
Posted on 04 Apr 2023
Print article
Image: The BOND-III fully automated IHC and ISH staining system (Photo courtesy of Leica)
Image: The BOND-III fully automated IHC and ISH staining system (Photo courtesy of Leica)

Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, with around 3-5% of cases attributed to Lynch syndrome - an uncommon hereditary cancer predisposition syndrome that elevates the risk of developing CRC. The current guidelines for cancer treatment emphasize the significance of testing for Mismatch Repair (MMR) status in all newly diagnosed CRCs as an initial screening procedure for Lynch syndrome. Immunohistochemistry (IHC), an increasingly prevalent clinical practice, is one of the suggested methods of testing.

Leica Biosystems’ (Nussloch, Germany) US FDA-cleared BOND MMR Antibody Panel now offers a high-performing IHC MMR option when screening CRC patients for identifying probable Lynch syndrome. The BOND MMR Antibody Panel is now available for clinical use on the BOND-III and BOND-MAX IHC automated instruments.

"Pathologists can utilize the Leica Biosystems BOND MMR Antibody Panel on the BOND-III for clear, accurate assessment of mismatch repair protein status in only 2.5 hours," said Dr. Robert Monroe, Chief Medical Officer at Leica Biosystems. "With this panel, clinicians can feel increased confidence in their MMR results."

"Leica Biosystems is proud to help our customers continue the fight against cancer through the fast, accurate results of the BOND MMR Antibody Panel, which provides the clinicians an important piece of the diagnostic puzzle in aiding the detection of Lynch syndrome," added Gustavo Perez-Fernandez, President of Leica Biosystems. "Our test enables targeted treatment for patients, supporting our mission of Advancing Cancer Diagnostics, Improving Lives."

Related Links:
Leica Biosystems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.